Browsing category:

Anti-Diabetic


Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on March 19, 2013 the initiation of a novel clinical trial for linagliptin. Coined MARLINA, this Phase IIIb trial will evaluate the glycemic efficacy and safety of linagliptin in patients with type 2 diabetes who have prevalent albuminuria. This patient population, suffering from albuminuria, will[…]

Read More

Is Testosterone a potential preventative treatment for type 2 diabetes? Researchers at the University of Adelaide in Australia are hopeful that their latest research will be the kick-start for trials of testosterone as a preventative for this encompassing from of diabetes. Results from early stages of this current study, which were discussed at the 10th[…]

Read More

Canagliflozin FDA approved as a new and unique treatment for type 2 diabetes. There were nine clinical trials involving more than 10,285 patients with type 2 diabetes. The trials showed positive results with greater glycemic control in patients. The recommended use for Canagliflozin patients includes a strict regimen of diet and exercise. The drug also outperforms similar[…]

Read More

An FDA Advisory Committee recommended the approval of Canagliflozin, CAS# 842133-18-0, for the treatment of type 2 diabetes. The approval in January 2013 was an encouraging move for Johnson and Johnson, who will market Canagliflozin as the brand Invokana. As an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least[…]

Read More

As a treatment for Type 2 diabetes lixisenatide is approved by the EU and currently under review as a New Drug Application {NDA} by the FDA. Sanofi is preparing to launch lixisenatide in the European Union as in the latter of first quarter 2013, with the proprietary name Lyxumia. What makes lixisenatide unique is not[…]

Read More

Alogliptin is a current newsmaker in the pharmaceutical industry. On January 25, 2013 Takeda announced that Alogliptin, CAS# 850649-62-6, was approved alongside Metformin HCl, CAS# 1115-70-4, in the novel type 2 diabetes medication Kazano. As an efficacious and highly selective DPP-4 inhibitor, Alogliptin, when combined in this single dose tablet with metformin HCI effectively aids[…]

Read More

Exenatide, CAS number 141758-74-9 is an injectable prescription medication that helps to improve blood sugar, or glucose control in adults with type 2 diabetes mellitus. Exenatide, derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US, is a functional analog of Glucagon-Like Peptide-1 (GLP-1), a naturally[…]

Read More

As a chronic disease which occurs when the body does not properly produce, or use the hormone insulin, type 2 diabetes has become a worldwide problem. Roughly 25.8 million Americans and an estimated 366 million people worldwide have diabetes, according to the CDC and 2011 data from the IDF. Type 2 diabetes accounts for 90-95[…]

Read More

Glipizide, CAS number 29094-61-9, is also known as Glucotrol XL, which is marketed by Pfizer. With the patent due to expire in January of 2014, glipizide is set up for success as a generic alternative treatment for patients with type 2 diabetes. As an oral blood-glucose-lowering drug of the sulfonylurea class, glipizide is offered in[…]

Read More